7713-76-0

Usage

Uses

Used in Pharmaceutical Synthesis:
2-(4-bromophenyl)-N-methylacetamide is utilized as a key building block in the creation of various pharmaceutical compounds. Its unique structure allows for the development of new drugs with specific therapeutic targets, contributing to advancements in medicinal chemistry.
Used in Organic Material Synthesis:
In the field of organic materials, 2-(4-bromophenyl)-N-methylacetamide serves as a crucial component in the synthesis of novel materials with tailored properties. Its incorporation into these materials can enhance their performance in various applications, such as electronics, coatings, and adhesives.
Used in Biological Research:
Due to its potential biological activities, 2-(4-bromophenyl)-N-methylacetamide is employed in biological research to study its pharmacological properties. This research can lead to a better understanding of its interactions with biological systems and the discovery of new therapeutic applications.
Safety Considerations:
It is important to handle 2-(4-bromophenyl)-N-methylacetamide with care, as it may pose health hazards if swallowed, inhaled, or exposed to skin and eyes. Proper safety measures should be taken during its synthesis, storage, and use to minimize potential risks.

InChI:InChI=1/C9H10BrNO/c1-11-9(12)6-7-2-4-8(10)5-3-7/h2-5H,6H2,1H3,(H,11,12)

Upstream product

• 109-72-8 n-butyllithium 
• 149652-50-6 2-(4-bromophenyl)-N-methoxy-N-methylacetamide 
• 37859-24-8 2-(4-bromophenyl)acetyl chloride 
• 74-89-5 methylamine 
• 7713-59-9 4-(4-bromo-phenyl)-2-methyl-2H-isoxazol-5-one 
• 7713-75-9 <4-Brom-phenyl>-malonsaeure-N-methylamid 

Downstream Products

• 214209-95-7 2-(4-bromophenyl)-N-methylethan-1-amine hydrochloride 
• 877265-10-6 7-bromo-2-methyl-1,4-dihydro-2H-isoquinolin-3-one 
• 725683-06-7 2-(4-bromophenyl)-N-methylethan-1-amine 
• 1256359-34-8 2-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-N-methylethanamide 
• 865111-81-5 1,1-dimethylethyl 7-{4-[2-(methylamino)-2-oxoethyl]phenyl}-1,2,4,5-tetrahydro-3H-3-benzazepine-3-carboxylate 

Relevant academic research and scientific papers

One-pot sequential 1,2-addition, Pd-catalysed cross-coupling of organolithium reagents with Weinreb amides

An efficient sequential 1,2-addition/cross-coupling of Weinreb amides with two organolithium reagents is reported. This synthetic approach allows access to a wide variety of functionalized ketones in a modular way. The one-pot procedure presented here takes advantage of a kinetically stable tetrahedral Weinreb intermediate during subsequent Pd-catalyzed cross-coupling with the second organolithium reagent leading, within short reaction times and under mild conditions, to the formation of ketones in excellent overall yields.

Initial process development and scale-up of the synthesis of a triple reuptake inhibitor ALB 109780

Early process development toward a triple reuptake inhibitor is described. Three different routes were evaluated; one of them was optimized and scaled up to generate 470 g of API as this route minimized the formation of undesired side products. The select

Process development and pilot-scale synthesis of new cyclization conditions of substituted phenylacetamides to tetrahydroisoquinoline-2-ones using Eaton's reagent

Tetrahydroisoquinoline is a ubiquitous structural framework presented in numerous pharmacologically relevant molecules. Although accessible by the Pictet-Spengler cyclization, conditions commonly used for such cyclizations are often difficult to implement on scale. Herein, we report the development of a scaleable approach utilizing Eaton's reagent for the cyclization of substituted phenylacetamide analogues to tetrahydroisoquinoline-2-one. The development, optimization, and safety hazard evaluations, which outline the benefits and ease of workup of this new process, are discussed.

MACROCYCLIC FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS

The present invention relates generally to novel macrocycles of Formula (I): or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, thereof, wherein the variables A, B, L, M, W, Z, R1, R2, R3, R4, R5, R6, R7, R8, R9, and R10 are as defined herein. These compounds are selective inhibitors of the serine protease coagulation factor VIIa which can be used as medicaments.